The mammalian hypothalamus regulates key homeostatic and neuroendocrine functions ranging from circadian rhythm and energy balance to growth and reproductive cycles via the hypothalamic-pituitary and hypothalamic-thyroid axes. In addition to its neurones, tanycytes are taking centre stage in the short-and long-term aug- 
| INTRODUC TI ON
Growing evidence shows that, in addition to hypothalamic neurones, tanycytes act as sensors, mediators and effectors for critical processes that underpin the homeostatic and neuroendocrine functions of the hypothalamus; for example, sensing of metabolites and micronutrients and trafficking of peripheral and central signals such as leptin and gonadotrophin-releasing hormone. 1, 2 Moreover, a subset of tanycytes acts as bona fide neural stem/progenitor cells in the postnatal and adult hypothalamus, capable of generating new energy balance-regulating neurones and glia. [3] [4] [5] Tanycytes are residual radial glial-like cells that occupy the floor and ventrolateral walls of the third ventricle (3V). They have been subdivided into four main subtypes:
β2, β1 and α2, α1, according to a combination of projection trajectory, morphology, barrier properties, cilia arrangement and positioning within or outside marker domains within the 3V wall. 1 Commonly, their apical surface is exposed to the cerebrospinal fluid, whereas their basal processes either contact the portal capillaries of the central (β2-tanycytes) and lateral (β1-tanycytes) median eminence, or terminate within the arcuate or ventromedial and dorsomedial nuclei C γ. 6, 7 The remaining FGFs (FGF11-14) function intracellularly in a receptor-independent manner. 8 FGFR signalling can modulate diverse aspects of cell behaviour in a cell-type specific manner. This is achieved partly via differential levels of signalling, established by intracellular negative feedback loop regulators such as Sproutys (Spry) and Map-kinase phosphatases (Mkp). 9 Tissue specificity of the action of FGF is governed by target cell expression of the socalled IIIb or IIIc alternatively-spliced receptor isoforms that engage a mutually-exclusive set of FGFs. 10 Moreover, co-factors such as sulphated proteoglycans and β-Klotho molecules not only facilitate focal FGF/FGFR signalling, but also determine the range of extracellular FGF diffusion. For example, peripherally generated FGF19 and FGF21 evade entrapment by heparan sulphate proteoglycans to act as circulating hormones in the metabolic control of energy homeostasis, with potential clinical applications in the management of type 2 diabetes.
11,12
Exogenous FGF2 is a potent mitogen for hypothalamic ependymal and neural cells in vitro and in vivo. 5, 13 Levels of FGF1 show a dramatic postprandial rise in the cerebrospinal fluid, 14 
| MATERIAL S AND ME THODS

| Animals
Both male and female mice ranging in age from 30 to 80 days of age were used. All mice were bred and maintained on a mixed 
| Tissue isolation and preparation
Mice were killed by CO 2 asphyxiation and brains were then dissected out and fixed for 4-16 hours overnight in 4% paraformaldehyde (PFA) (pH 7.0) at 4°C. For fresh tissue and mRNA isolation, mice were killed by cervical dislocation and microdissected hypothalami were flash frozen in cryotubes on dry ice and stored at −80°C. To generate cryostat sections, the brains were washed with diethyl pyrocarbonate (DEPC)-treated PBS (DEPC-PBS) and cryo-protected in 30% w/v sucrose/DEPC-PBS solution for 48 hours at 4°C. Thereafter, they
were placed in cryomoulds filled with optimal cutting temperature (OCT) compound, allowed to set on dry ice, and stored at −80°C.
Coronal sections, 20 μm thick, containing the central part of median eminence (bregma −1.45 to −1.94) were then generated using a freezing microtome (MicroM HM560; Thermo Fisher Scientific, Waltham, MA, USA) and thaw-mounted onto previously baked (180°C, overnight) Superfrost (Thermo Fisher Scientific) slides, and stored at −80°C until use.
To generate vibratome sections, PFA-fixed brains were first dehydrated in ascending concentrations (30%, 50%, 70%, 90%; 1 hour per dilution) of ethanol, before being stored at 4°C in absolute ethanol.
Just before use, brains were rehydrated stepwise back to PBS and embedded in 3% w/v agar overnight. Coronal sections, 60 μm thick, containing median eminence (bregma −1.46 to −2.18) were then generated using a vibrating microtome (Leica Microsystems, Wetzlar, Germany) and stored in PBS until use.
| RNA isolation
Microdissected hypothalami were homogenised by trituration in 1 mL of Trizol (Invitrogen, Carlsbad, CA, USA) before addition of 200 μL of chloroform. Following centrifugation (15 minutes at 12 000 g), RNA was precipitated from the aqueous layer by addition of 500 μL of isopropanol. Samples were briefly vortexed, allowed to stand for 10 minutes at room temperature and then centrifuged (15 minutes at 12 000 g). The resulting supernatant was carefully removed before adding 1 mL of 75% ethanol diluted in molecular grade water (Sigma, St Louis, MO, USA) and further centrifugation (12 minutes at 5200 g). The RNA pellet was then briefly air dried, re-suspended in molecular grade water and incubated at 55°C for 10 minutes. RNA concentration and quality was determined using a spectrophotometer (Nanodrop ND-1000; Thermo Fisher Scientific) and samples were stored at −80°C until use.
| Primer design and RT-PCR
Gene specific primer pairs (see Supporting information, Table S1 ) for use in RT-PCR reactions were designed using NCBI primer-BLAST ( https ://www.ncbi.nlm.nih.gov/tools/ primer-blast ), aiming for regions of least sequence conservation between related family members, 23 and amplicons that are not only small, but are also comparable in size across the related family members (see Supporting information, 
| Riboprobe synthesis and In situ hybridisation (ISH)
Digoxigenin-labelled antisense RNA probes were generated using T7 RNA polymerase enzyme (Thermo Fisher Scientific) and either T7-tagged RT-PCR amplicons (above) or linearised plasmids encoding gene-specific cDNAs (see Supporting information, 
| Immunohistochemistry, immmunofluorescence labelling and X-gal staining
Non-specific binding sites were blocked by a 2-hour incubation in a solution of 20% hiNGS/1% Triton X-100 (TX)/PBS, before application of primary antibodies (see Supporting information, Table S2) overnight at 4°C in 0.2% hiNGS/0.1% TX/PBS. Excess primary antibodies were removed by five 1-hour washes at room temperature with a 0.2% hiNGS/0.1% TX solution and this was followed by overnight incubation with the relevant secondary fluorophore conjugated antibodies (see Supporting information, Table S2 For combined ISH and immunohistochemistry, after completion of the ISH protocol, sections were incubated for 1 hour in blocking solution (10% hiNGS/0.3% TX/PBS) followed by overnight incubation at 4°C
with mouse anti-glial fibrillary acidic protein (GFAP), rabbit anti-GFAP or mouse anti-S100β antibodies (see Supporting information, Table S2 ) diluted in 0.2% hiNGS/0.1% TX/PBS. After three 5-minute PBS washes, the 3,3'-diaminobenzidine (DAB) staining reaction was performed using a DAB peroxidase substrate kit (Vector Laboratories) in accordance with the manufacturer's instructions. After five 1-minute washes with ddH 2 O, sections were preserved by coverslipping with 50% glycerol/PBS solution.
To detect the product of the lacZ reporter gene, β-galactosi- 
| Image capture and analysis
All images were captured using a Axioplan 2 microscope and axiovision, version 4.8 (Carl Zeiss, Oberkochen, Germany). High magnification of phophorylated extracellular signal-regulated kinase (pERK)
immunostaining was imaged and analysed by 3D reconstruction of 1-μm optical sections (z stacks), captured using an Apotome attachment.
Images were post-processed (adjustment of brightness, contrast, levels and unsharp mask) using fiji ( https ://fiji.sc), axiovision and photoshop (Adobe Systems Inc., San Jose, CA, USA) software packages.
| RE SULTS
| Global analysis: detection of distinct FGFs and signalling modulators and predominance of FGFR IIIc isoforms
To determine which components of the FGF signalling system need to be mapped spatially in the hypothalamus, we first undertook a gross RT-PCR screen of mRNA expression derived from 30-45-day-old (P30-P45) animals. Industrially pre-aliquoted substrates (illustra Ready-To-Go beads; GE Healthcare Life Sciences) were used to amplify comparable amplicon sizes. We opted for an RNA-based and gene-reporter analysis (here and below) because antibodies to FGFs often detect multiple related family members and, in the case of FGFRs, they fail to discriminate between isoforms in immunolabelling studies. Animals older than P30 were used because the full spectrum of tanycytes subtypes, as well as the connectivity of hypothalamic neurones, is fully established by this age. Table S1 ) detected products of the expected size for Fgf1, 2, 5, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 20 Underlined numbers and letters denote a lack of detection of the relevant genes. Faint bands for Fgfr2 IIIb isoform and Fgf3 are nonspecific products, whereas all other RT-PCR products match the expected amplicon size, as predicted by use of primers listed in the Supporting information (Table S1 ). Multiple Fgf5 and Fgf8 products possibly represent isoforms of these genes Figure 1C ). Pea3 (also known as Etv4), a transcriptional target of FGF signalling, was also present.
This broad screen reveals that various components of the FGF signalling pathway are in place to mediate exogenous and to potentially augment endogenous FGF signalling in the hypothalamus.
| Predominance of FGFR1 and FGFR2, in the β-tanycyte domain
The gross RT-PCR screen (above) was performed using bulk tissue that contains multiple cell compartments: the median eminence (ME), the ependymal cell wall and the hypothalamic parenchyma. To Figure S1 ), the ISH analysis was combined with mouse anti-GFAP immunolabelling to investigate the selective expression of candidate genes within α-vs β-tanycyte subtypes.
We found that Fgfr1 and Fgfr2 are expressed predominantly in the GFAP-ve β-tanycyte domain (Figure 2A,A′,B) . Interestingly, the strongest Fgfr1 signal was observed in the floor of the 3V, which harbours the β2 subtype ( Figure 2A′ ), whereas Fgfr2 was equally strong in both β2-and β1-tanycyte domains, as well as the transition zone between β1-and α-tanycytes ( Figure 2B ). Fgfr1 expression was also detected in cells of the ARC, DMN and LHA, with strongest expression in the VMN (Figure 2A ). By contrast, Fgfr2 riboprobes only weakly stained cells in the ARC, VMN, DMN and LHA, as well as subependymal cells of the ME ( Figure 2B ; data not shown).
Interestingly, Fgfr3 expression was absent from the ependymal cell wall altogether, instead being abundant in cells scattered uniformly throughout the hypothalamic parenchyma, reminiscent of glial cell distribution ( Figure 2C ), as well as spare cells in the ME.
We combined Fgfr3 in situ with immunolabelling for glial/progenitor cell marker, S100β, only to find prevalent co-expression of these markers, confirming the glial identity of most Fgfr3-expressing cells Figure 3A′ ). By contrast, use of Spry2 riboprobes ( Figure 3B ) showed a more restricted pattern, composed of a weak signal in β-tanycytes, and scattered expression in the ARC, LHA and subependymal ME.
Spry3 ISH reactions produced a weak background signal. Mkp3 signal was restricted to scant cells in the LHA/tuberal nucleus ( Figure 3C ).
Another transcriptional target of FGF signalling is the transcription factor Etv4 (Pea3) [16] [17] [18] [19] . To detect the domain of its expres- 
| FGF ligands are expressed in tanycytes in two distinct patterns
The presence of FGFRs (IIIc isoforms) and FGF signalling modulators in the hypothalamus is suggestive of a necessity for cognate ligand(s). To delineate the cohort of putative ligands involved, we performed ISH using Fgf-specific cRNA probes and used transgenic reporter mice. Four FGF candidates and two main domains of expression emerged from this screen.
The expression domain of Fgf1 and Fgf9 overlapped in the 3V
wall with a restriction to the α-tanycyte domain ( Figure 4A′ -A″,B′-B′). 
Interestingly, ventricular expression of
| Restriction of intracellular FGFs to the parenchymal cell compartment
ISH with cRNA probes for intracellular FGFs (11 to 14) revealed a predominant expression in the hypothalamic parenchyma and subependymal cells in the ME but a notable absence from tanycytes themselves.
Fgf12 expression showed the broadest pattern, being present in the DMN, ARC and LHA, most strongly in the VMN ( Figure 4E ). Fgf13 was restricted to sparse cells in the DMN and ARC and rarely in cells of LHA and ventrolateral VMN ( Figure 4F ; data not shown). Fgf14 was expressed
by only a few cells in the most dorsomedial part of the ARC ( Figure 4G ).
| D ISCUSS I ON
Extrinsic modulation of FGF signalling in rodents can elicit dramatic changes in metabolism, body weight and plasma glucose clearance, The therapeutic use of FGFs requires a better understanding of the foci and mechanisms by which FGFs operate, and whether endogenous hypothalamic FGF signalling normally has a role to play in these processes.
On face value, our results, summarised in Table 1 
| Comparison with previous profiling studies of the FGF signalling pathway in the hypothalamus
Several surverys and atlases [29] [30] [31] [32] Recent studies show that the 3V epithelium is highly compartmen- Figure S3 ) in a similar pattern to that reported previously. 37 The presence of FGF pathway genes involving cell proliferation, differentiation, migration or cytoskeletal remodelling. 7 We showed that FGFR1 and FGFR2 are restricted to β-tanycytes, where they could regulate cell proliferation and differentation of these newly-identified stem/progenitor cells. 38 Indeed, some studies have envisaged changes in postnatal hypothalamic neurogliogenesis as a contributory mechanism to body weight change and insulin-independent glucose lowering effects of exogenous FGFs. 11, 39 Equally, these effects may involve short-or long-term alterations in barrier properties, nutrient sensing, and cargoing or trafficking of metabolic signals and hormones by β-tanycytes.
2,38,40
These cells are certainly enriched in the endocytotic pathway molecules, such as caveolins, 41 which have been shown to control FGF2/ FGFR1 signalling in other cell types and settings. 42 Within the 3V epithelium, β-tanycytes also uniquely possess primary cilia, 33 as well as receptors for VEGFR3, 43 and other key regulators of energy homeostasis such as ciliary neurotrophic factor 44 and leptin. 38 This suggests that β-tanycytes may also be responsive to Hedgehog signalling and/ or act as a hub of cell signalling, or that their biology relies on synergy between multiple signalling pathways. Therefore, fine dissection of other signalling pathways in tanycytes is warranted.
β2-tanycytes are radial glial-like cells whose processes span the width of the median eminence. Therefore, it is possible that FGFR1
and FGFR2 operate not only on their apical surfaces, exposed to ventricular-derived FGFs, but also on their basal surfaces, in close proximity to the capillary plexus of the outer ME, where capillary fenestrations would readily allow exposure to circulating FGFs.
Hints for the heterogeneity and paracine response of β-tanycytes to 
| Lessons from human mutations and transgenic mouse models of the FGF signalling pathway
Is the prediction of FGFR1-3 IIIc and FGF1, 2, 9 and 18 as key endogenous canonical FGF signalling partners in mouse hypothalamus, borne out by naturally-occuring human mutations or experimental transgenic alleles? With minor exceptions (e.g. murine Fgf15 vs human Fgf19), both the human and mouse FGF signalling apparatus is highly conserved in expression domain and function. Moreover, tanycytes have also been identified in the human hypothalamus 54 and human and rodents broadly share common mechanisms for the regulation of energy balance. A spectrum of dominant acting mutations in human FGFR1 and FGFR2 causes rare congenital skeletal syndromes, such as Apert and Pfeiffer. 6 However, no association between these syndromes and predisposition or resistance to diabetes and obesity has been reported. By contrast, a significant number of achondroplasia patients that carry activating FGFR3 mutations also manifest atypical obesity. 55 
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